

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 9/06	A1	(11) International Publication Number: WO 97/10808 (43) International Publication Date: 27 March 1997 (27.03.97)
(21) International Application Number: PCT/US96/13098 (22) International Filing Date: 12 August 1996 (12.08.96) (30) Priority Data: 08/531,290 20 September 1995 (20.09.95) US (71)(72) Applicant and Inventor: PERRICONE, Nicholas, V. [US/US]; Suite 2A, 35 Pleasant Street, Meriden, CT 06450 (US). (74) Agents: ST. ONGE, Ronald, J. et al.; St. Onge Steward Johnston & Reens, 986 Bedford Street, Stamford, CT 06905- 5619 (US).		(81) Designated States: CA, JP, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: LIPOIC ACID IN TOPICAL COMPOSITIONS (57) Abstract In a method for the prevention and/or treatment of skin damage, particularly inflammation and aging, a composition containing lipoic acid and/or a lipoic acid derivative is topically applied to affected skin areas. A fat-soluble fatty acid ester of ascorbic acid such as palmitoyl ascorbate and/or tocotrienol is preferably applied with the lipoic acid or derivative in association with a dermatologically acceptable carrier.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

LIPOIC ACID IN TOPICAL COMPOSITIONS

Technical Field

This invention relates to the topical application of compositions containing lipoic acid for the prevention and/or treatment of damage to skin, particularly for the treatment or prevention of inflammatory and aging effects from sunlight and chemical damage.

Background of the Invention

Lipoic acid was originally identified as a bacterial growth factor present in the water-soluble fraction of liver and yeast. It was found to be necessary for the oxidative decarboxylation of pyruvic acid by *Streptococcus fecalis* and for the growth of *Tetrahymena gelii*, and replaced acetate for the growth of *Lactobacillus casei*. It has been variously known as acetate replacing factor, protogen A, and pyruvate oxidation factor.

Subsequent research showed that lipoic acid (LA) was a growth factor for many bacteria and protozoa and it served as a prosthetic group, coenzyme, or substrate in plants, microorganisms, and animal tissues. Elucidation of its structure and function determined that it is a co-factor for α -keto-dehydrogenase complexes, typically bound as lipoamide, that participates in acyl transfer reactions. Its reduced form, dihydrolipoic acid (DHLA), is a potent sulfhydryl reductant. In aqueous systems,

both LA and DHLA exhibit antioxidant actions (briefly reviewed in the introduction of Maitra, I., et al., *Free Rad. Biol. Med.* 18:823-829 (1995)). LA has been shown to maintain microsomal protein thiols, protect against hemolysis, and protect against neurological disorders (*ibid.*). The protective effect of dietary supplementation of LA against ischemia/reperfusion injury in the Langendorff isolated heart model has also been demonstrated (*ibid.*). LA has been used in treating liver cirrhosis, atherosclerosis, and polyneuritis of diabetes mellitus, diseases in which oxidative stress plays a role (*ibid.*). It has also been used as an antidote to poisonous mushrooms (particularly *Amanita* species, *Merck Index*, 11th ed., 1989, entry 9255).

The antioxidant activity of lipoic acid appears to prevent free radical damage to cells and cell components. Free radical damage is most evident in cellular membranes because of the density of the molecular structure of the membranes. It is currently hypothesized that cell membrane aging leads to all of the various cellular changes seen in aging, such as decreased RNA production, decreased protein production, and faulty enzyme action.

Inflammation in skin is mediated by several active chemicals and metabolites of arachidonic acid. Arachidonic acid is oxidized by cyclo-oxygenase and lipoxygenase to active metabolites such as the leukotrienes and 5- and 12- hydroxyeicosatetraenoic acid (HETES). Within the arachidonic acid cascade, many free radicals are generated, which both perpetuate and magnify the inflammatory cascade, resulting in skin damage and manifested clinically as erythema.

Early suggestions for dealing with erythema and aging effects in skin were predominantly aimed at lubrications and emollients through use of topical composi-

tions containing soothing agents, e.g., as exemplified by commercial hand lotion products and the like. More recently, attention has been directed to agents which address the underlying processes involved in skin damage, such as the free radical generation processes. In this regard, investigations have been made with respect to the antioxidants vitamin E and vitamin C to quench free radicals on the surface of the skin and to protect lipid membranes intracellularly (Wilson, R., *Drug and Cosmetic Industry*, 32-34, 38, and 68, August 1992).

It would be desirable to have alternative topical compositions for anti-inflammatory and anti-aging effects observed in skin, particularly compositions that are efficient in free radical scavenging in membranes.

15 Summary of the Invention

It is an object of this invention to provide a method and composition for the treatment and/or prevention of skin damage, particularly skin inflammation and aging mediated by free radicals.

20 It is another and more specific object of the invention to provide a topical composition and method for a preventive regimen and/or therapy based upon topical application to exposed or affected skin areas of an active agent or derivative thereof, in association with a dermatologically acceptable carrier or vehicle.

These and other objects are accomplished by the present invention, which provides a method for the prevention and/or treatment of skin inflammation, aging and other skin damage, which comprises topical application to the exposed or affected skin areas of an effective amount

of lipoic acid, lipoic acid derivatives or mixtures thereof in a dermatologically acceptable carrier.

In many embodiments, tocotrienols or derivatives thereof or vitamin E compositions enriched with tocotrienols or tocotrienol derivatives are included in the lipoic acid composition. Ascorbic acid, particularly fat-soluble fatty acid esters of ascorbic acid such as ascorbyl palmitate, can, optionally, also be utilized for further enhancing the efficacy of the therapeutic or prophylactic treatment. Other reductants such as α -hydroxy acids and the like may also be added to the composition.

In one particularly preferred embodiment, the topical composition contains lipoic acid or dihydrolipoic acid or mixtures thereof, ascorbyl palmitate, and tocotrienol as active ingredients.

In the preferred practice of the invention, the lipoic acid (or derivative) is applied in admixture with a dermatologically acceptable carrier or vehicle (e.g., as a lotion, cream, ointment, soap, or the like) so as to facilitate topical application and, in some cases, provide additional therapeutic effects as might be brought about, e.g., by moisturizing of the affected skin areas. As noted, other ingredients, particularly ascorbyl palmitate and/or tocotrienol, can be advantageously included in the compositions.

The amount of lipoic acid or derivative thereof (hereinafter referred to collectively as lipoic for ease of reference) necessary to bring about enhanced prevention and/or therapeutic treatment of skin damage is not fixed *per se*, and necessarily is dependent upon the identity and form of lipoic acid employed, the amount and type of any additional ingredients used, particularly

those that appear to exhibit synergistic effects (to be discussed more fully below), the user's skin type, and, where present, the severity and extent of the patient's pathological skin or hair condition. Generally, the

5 lipoic acid or composition containing it is topically applied in effective amounts to skin areas which have been damaged or aged, or which are susceptible to damage, because of inflammation or aging.

In one embodiment, the composition contains from


10 about 0.25 to about 5 weight %, preferably from about 1% to about 3%, lipoic acid or dihydrolipoic acid. In one embodiment, 2% lipoic acid is employed.

Detailed Description of the Invention

This invention is based upon the finding that

15 lipoic acid and dihydrolipoic acid are useful for the treatment and prevention of damaged skin. Lipoic acid and its derivatives also augment the efficacy of other ingredients in topical compositions for inflammation, aging and other skin damage.

20 As used herein, the term "lipoic acid" encompasses thioctic acid (1,2-dithiolane-3-pentanoic acid; 1,2-dithiolane-3-valeric acid), which has the following general formula:



25 It is marketed under the tradenames Biletan®, Lipoicin®, Thioctacid®, Thioctan®, Tioctan®, and Tioctidasi®.

Lipoic acid derivatives include thioctic acid esters, particularly alkyl esters such as fatty acid esters, amides, particularly those isolated from or mim-

icking naturally occurring lipoamides, and salts, particularly alkali metal salts, and specifically includes the reduced form, dihydrolipoic acid. Since lipoic acid is fat- rather than water-soluble, the water-soluble sodium salt is especially useful in embodiments that have an aqueous base. Derivatives may also include those involving other reactive groups known to those skilled in the art. As used herein, the term "derivatives" includes metabolic precursors of lipoic acid. Where lipoic acid derivatives are employed, they must be functionally equivalent to lipoic acid.

As mentioned above, lipoic acid is fat-soluble. Therefore, lipoic acid preparations can be applied neat to skin areas subject to damage or already damaged. It is an advantage of the invention that the active compound is fatty so that it physically contributes to the lubrication and soothing of affected skin areas.

However, only effective amounts of lipoic acid are needed to prevent or treat skin damage, so generally topical application to exposed or affected skin sites is accomplished in association with a carrier, and particularly one in which the active ingredient is soluble *per se* or is effectively solubilized (e.g., as an emulsion or microemulsion). It is necessary that the carrier be inert in the sense of not bringing about a deactivation of the lipoic acid or derivative, and in the sense of not bringing about any adverse effect on the skin areas to which it is applied.

Suitable carriers include water, alcohols, oils and the like, chosen for their ability to dissolve or disperse the active ingredients at concentrations of active ingredients most suitable for use in the therapeutic treatment. Generally, even low concentrations of active ingredients in a carrier will be suitable, requiring only

that more frequent topical application be resorted to. As a practical matter, however, to avoid the need for repeated application, it is desirable that the topically applied composition be formulated to contain at least
5 about 0.25% to about 5% by weight, more preferably from about 1 % to about 3% by weight, lipoic acid or a derivative thereof, and accordingly, carriers will be chosen which can solubilize or disperse the active ingredients at such concentrations. One efficacious embodiment con-
10 tains about 2% by weight lipoic acid.

While the carrier for lipoic acid can consist of a relatively simple solvent or dispersant such as oils, it is generally preferred that the carrier comprise a composition more conducive to topical application, and partic-
15 ularly one which will form a film or layer on the skin to which it is applied so as to localize the application and provide some resistance to perspiration and/or one which aids in percutaneous delivery and penetration of the active ingredients into lipid layers. Many such composi-
20 tions are known in the art, and can take the form of lotions, creams, gels or even solid compositions (e.g., stick-form preparations). Typical compositions include lotions containing water and/or alcohols and emollients such as hydrocarbon oils and waxes, silicone oils, hyal-
25 uronic acid, vegetable, animal or marine fats or oils, glyceride derivatives, fatty acids or fatty acid esters or alcohols or alcohol ethers, lanolin and derivatives, polyhydric alcohols or esters, wax esters, sterols, phospholipids and the like, and generally also emulsifiers
30 (nonionic, cationic or anionic), although some of the emollients inherently possess emulsifying properties. These same general ingredients can be formulated into a cream rather than a lotion, or into gels, or into solid sticks by utilization of different proportions of the
35 ingredients and/or by inclusion of thickening agents such as gums or other forms of hydrophillic colloids. Such

compositions are referred to herein as dermatologically acceptable carriers. Most preferred for skin are those carriers which are fat-soluble, i.e., those which can effectively penetrate skin layers and deliver the active lipoic acid to the lipid-rich layers of the skin.

Many preferred embodiments of this invention contain at least one or two other active ingredients in addition to lipoic acid. It has been observed that lipoic acid had a protective effect on components of a lens antioxidant system comprising ascorbate/dehydroascorbate (Maitra, et al., cited above); the same authors suggested it may be of possible usefulness in the prevention of cataracts. In this invention involving other tissues, fat-soluble fatty acid esters of ascorbic acid (vitamin C) may be added to the lipoic acid composition in some embodiments. The more oxidation-resistant saturated fatty acid esters of ascorbic acid are preferred, including, but not limited to, ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl behenate. Ascorbyl palmitate is used in one embodiment. As denoted herein, where fatty acid esters are described, e.g., ascorbyl stearate, compositions having predominantly that ester, e.g., predominantly stearate, are included. The esters may be prepared using hydrogenated oils or fats, or fractions thereof, and contain small amounts of another ester. Ascorbyl stearate prepared using canola, for example, commonly contain about 4% ascorbyl palmitate.

Tocotrienol may also be added to the lipoic acid composition, alone or in combination with an ascorbyl fatty acid ester in some embodiments. Dihydrolipoic acid has been shown to enhance vitamin E recycling in other systems (*ibid.*). The term "tocotrienol" encompasses counterparts of tocopherol (vitamin E) that bear unsaturated tails, and include, but not limited to, α -, β -, γ -,

and δ -tocotrienols, desmethyl-tocotrienol, didesmethyl-tocotrienol (occurring in sunflower seeds, vegetable oils, barley, brewer's grains, oats, and African violets), their synthetic counterparts, their counterparts
5 having methylated or demethylated chroman rings, and mixtures thereof. The double bonds may be *cis* or *trans* or mixtures thereof.

In many embodiments utilizing tocotrienol in the composition, the tocotrienol is isolated from natural
10 sources and added to the formulation as a tocotrienol-enriched vitamin E preparation. However, synthetic preparations may also be employed as well as mixtures of natural and synthetic vitamin E. Tocotrienol-enriched vitamin E preparations may be obtained by fractionating
15 vitamin E preparations to remove a portion of tocopherols and recover a preparation more highly concentrated in tocotrienol. Useful tocotrienols are natural products isolated, for example, from wheat germ oil, bran, or palm oil using high performance liquid chromatography, or
20 isolated by alcohol extraction and/or molecular distillation from barley, brewer's grain or oats. As used herein, the term "tocotrienols" includes tocotrienol-rich fractions obtained from these natural products as well as the pure compounds.

25 As with other vitamin E preparations, tocotrienol or tocotrienol-enriched preparations include those containing tocotrienol and, in some cases, tocopherol derivatives, particularly stabilized derivatives. These typically include derivatives related to the phenolic hydroxyl functionality, i.e., wherein it is acylated with an
30 organic acid to form an ester. Examples of such stabilized tocotrienols include, but are not limited to, tocotrienol acetate, tocotrienol succinate, and mixtures thereof. However, the derivatives may also include those
35 involving other reactive groups known to those skilled in

the art. Where tocotrienol derivatives are employed, they must be functionally equivalent to tocotrienol. Preferred derivatives contain both the chromanol nucleus and three double bonds in the hydrocarbon tail.

5 The combination of tocotrienol or tocotrienol-enriched vitamin E preparations and/or a fat-soluble vitamin C fatty acid ester, preferably both, in a dermatologically acceptable carrier with lipoic acid or a derivative is especially advantageous in compositions because
10 lipoic acid augments the efficacy of the other ingredients in the composition. The combination of up to three active ingredients readily solubilizes in the lipid-rich layers of the skin and together scavenge free radicals involved in aging, inflammation, and other skin damage.

15 The effectiveness of lipoic acid and lipoic acid derivatives, especially when employed in combination with ascorbyl fatty acid esters and/or tocotrienols, can be postulated as resulting from the antioxidant properties of active ingredients *per se*, which properties are unexpectedly retained and provided to a high degree when used
20 in concert with lipoic acid when these are delivered in combination to the skin in an extremely effective manner in an oil phase. The mechanism of the effect is not well understood, but may be related to the anti-oxidant properties of the active compounds and/or their interference
25 with chemical reactions.

 In terms of a possible explanation for the effectiveness of the active ingredients in the prevention or treatment of damage to the skin, it is noted that lipoic
30 acid, as an antioxidant, can scavenge free radicals such as the oxygen radicals created by exposure of skin cells to damage, as well as the generation of free radicals produced by normal metabolism extracellularly and intracellularly. Dihydrolipoic acid, for example, as a power-

ful antioxidant concentrated in cell membranes, can lessen erythema by the mechanism of free radical scavenging and chain breaking chemical reactions. Ascorbic acid is a powerful reducing agent that can prevent oxidative damage and regenerate chromanoxyl radicals formed as vitamin E derivatives scavenge radicals, reforming vitamin E that can scavenge more radicals. Preferred embodiments of this invention harness this synergistic effect.

In addition, ascorbic acid can increase cyclo-oxygenase activity in human cells. Cyclo-oxygenase is a key enzyme in the oxidation of arachadonic acid, which leads the formation of prostaglandins which in turn mediate inflammation.

Some embodiments further include α -hydroxy acid ingredients such as glycolic acid, hydroxymethylglycolic acid, lactic acid, glucuronic acid, galacturonic acid, gluconic acid, glucoheptonic acid, α -hydroxybutyric acid, α -hydroxyisobutyric acid, α -hydroxyvaleric acid, α -hydroxyisovaleric acid, α -hydroxycaproic acid, α -isocaproic acid, tartronic acid, tartaric acid, malic acid, hydroxyglutaric acid, hydroxyadipic acid, hydroxypimelic acid, muric acid, citric acid, isocitric acid, saccharic acid, dihydroxymaleic acid, dihydroxytartaric acid, and dihydroxyfumaric acid or derivatives of hydroxy acids such as pyruvic acid, methyl pyruvate, ethyl pyruvate, isopropyl pyruvate, benzoylformic acid, methyl benzoylformate, and ethyl benzoylformate.

Because cell aging is the result of free radical damage, it is apparent that lipoic acid and its derivatives are also effective in the prevention of cell aging, as are combinations with ascorbic acid fatty acid esters and tocotrienols. All the substances are fat-soluble and disperse within cell membranes, acting as free radical scavengers and neutralizers, and prevent the cross-link-

ing of cell membranes that is seen in the aging process. Once the cell membranes are cross-linked, the permeability of cell membranes increases, causing an inefficient exchange of nutrients and waste products within the cell.

5 The decreased cell permeability results in increased ionic concentration of potassium, which then causes decreased messenger RNA production. The increased ionic concentration also interferes with enzyme activity, as enzymes are very much dependent on ionic concentration

10 for their action.

In addition to decreased production of RNA, there is a marked decrease in the production of protein with aging, and therefore the cell cannot repair itself. The altered cellular membranes prevent removal of waste products in the cell, such as lipofucin, which is a histologic characteristic of all aging cells. Lipoic acid and its derivatives, by preventing free radical damage to cell membranes and preventing decreased permeability to cells, can theoretically prevent aging of the cell by

15 maintaining proper ionic concentration, proper disposal of waste products, and efficient protein and RNA production. Topical application of lipoic acid and its derivatives to skin can thus prevent cell aging, and the effect is pronounced when acting in concert with ascorbyl fatty

20 acid esters and/or tocotrienol.

25

The method of the present invention is particularly useful for the prevention of skin damage which may result from exposure to ultraviolet radiation, but, based upon the likely mechanism of action, also is useful in

30 general for treatment of any radiation-induced skin damage, particularly that associated with free radical related damage. As such, the topical application of lipoic acid according to the invention can also be effective for chronic administration to prevent the free radical damage

35 seen in the natural aging process of the skin and the

free radical damage caused by chronic exposure to sunlight. Lipoic acid, alone or with tocotrienol and/or ascorbyl fatty acid esters can thus be added to dermatological creams and emollients as well as to commercial
5 suncscreens to enhance their anti-aging and anti-cancer activity.

It is an advantage of the invention that, because of the efficiency of free radical scavenging and other biochemical mechanisms involved after application of
10 active ingredients to skin, compositions of the invention exhibit efficacy when applied to a variety of skin damaged conditions, including dry skin, psoriasis, and dermatitis (contact, irritant, and allergic). Compositions of the invention can also be used as a treatment after
15 burn.

Generally, the composition is topically applied to the affected skin areas in a predetermined or as-needed regimen to bring about improvement, it generally being the case that gradual improvement is noted with each
20 successive application. Insofar as has been determined based upon clinical studies to date, no adverse side effects are encountered.

Having described the invention with reference to particular compositions, theories of effectiveness, and
25 the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the appended claims. It is intended that all modifications and
30 variations be included within the scope of the invention. The claims are meant to cover the claimed components and steps in any sequence which is effective to meet the

objectives there intended, unless the context specifically indicates the contrary.

Claims

1. A method for treating or preventing skin damage, said method comprising topically applying to skin areas subject to such damage a composition containing an effective amount of an active compound selected from the group
5 consisting of lipoic acid, a lipoic acid derivative and mixtures thereof.

2. A method for the treatment or prevention of skin damage, said treatment or prevention comprising topically applying to skin areas subject to such damage a composition containing, in a dermatologically acceptable carrier,
5 an effective amount of each of two groups of compounds (a) and (b), wherein

(a) is an active compound selected from the group consisting of lipoic acid, a lipoic acid derivative, and mixtures thereof, and

10 (b) is a fat-soluble fatty acid ester of ascorbic acid.

3. A method according to claim 2 wherein the fat-soluble fatty acid ester of ascorbic acid is selected from the group consisting of ascorbyl palmitate, ascorbyl laurate, ascorbyl myristate, ascorbyl stearate, and mixtures
5 thereof.

4. A method according to claim 3 wherein the fat-soluble fatty acid ester of ascorbic acid is ascorbyl palmitate.

5. A method according to claims 1 to 4 wherein the active compound is selected from the group consisting of lipoic acid, lipoic acid esters, lipoic acid amides, salts of lipoic acid, dihydrolipoic acid, and mixtures
5 thereof.

6. A method according to claim 5 wherein the active compound is selected from the group consisting of lipoic acid, dihydrolipoic acid, and a mixture thereof.
7. A method according to claims 1 to 6 wherein the composition contains from about 0.25% to about 5% by weight active compound.
8. A method according to claims 1 to 7 wherein the composition further comprises a tocotrienol.
9. A method according to claims 1 to 8 wherein the composition further comprises an α -hydroxy acid.
10. In a topical composition for the treatment of inflammation or aging of skin in a dermatologically acceptable carrier, an improvement wherein, to augment the efficacy of the composition, said composition further comprises from about 0.25% to about 5% by weight an active ingredient selected from the group consisting of lipoic acid, dihydrolipoic acid, and mixtures thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/13098

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/06

US CL : 424/401

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/401

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MAITRA, I., et al. α -lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. Free Radical Biology & Medicine. 1995, Vol. 18, No. 4, pages 823-829.	1-4, 10



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"A"

document defining the general state of the art which is not considered to be of particular relevance

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"E"

earlier document published on or after the international filing date

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"A"

document member of the same patent family

Date of the actual completion of the international search

03 OCTOBER 1996

Date of mailing of the international search report

07 NOV 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RAJ BAWA, Ph.D.

Telephone No. (703) 308-2351

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/13098

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-9
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.